Concurrent Session 4 – Inflammation (Clinical)

Hydroxychloroquine in Hand OA; Results of the UK HERO Trial

Timeslot: Friday, April 28, 2017 - 5:00pm to 5:30pm


Hydroxychloroquine is used routinely for treating synovitis in inflammatory arthritis. In our 248 participant, multi-centre, 12 month, placebo-controlled RCT hydroxychloroquine was not more effective than placebo in reducing symptoms or radiographic progression in people with moderate to severe hand pain and radiographic OA. Baseline structural damage and ultrasound-synovitis did not affect response to hydroxychloroquine. Hydroxychloroquine was less costly but produced a smaller quality-adjusted life year gain than placebo. This calls into question our inclusion criteria for hand OA trials, where ultrasound-synovitis may not be as prevalent as in knee OA, but may also relate to appropriate molecular targeting or drug dosage.